, based on data from 406 patients.
In a study published online in The Lancet Infectious DiseasesMical Paul, MD, of Rambam Health Care Campus, Haifa, Israel, and colleagues randomized 198 patients to colistin alone and 208 to colistin plus meropenem (Lancet Infect Dis. 2018 Feb 15. ).
The demographics were similar between the groups and approximately 77% of patients in each group were infected with A. baumannii.